Tissue targeting in cancer: eIF4E's tale.
The eukaryotic translation initiation factor eIF4E is elevated in many human cancers. Tissue-specific targeting of eIF4E activity in ovarian cancer cells is achieved in cell culture and in mice by fusing a peptide corresponding to the eIF4E inhibitor, the eIF4E binding protein 1 (BP1), to an agonist of the gonadotropin receptor.
Borden
Katherine L B
KL
Institute of Research in Immunology and Cancer (IRIC), Department of Pathology and Cell Biology, Université de Montréal, Montreal, Quebec, Canada. katherine.borden@umontreal.ca
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D039561:Eukaryotic Initiation Factor-4E / Q000037:antagonists & inhibitors* / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D039561:Eukaryotic Initiation Factor-4E; D011993:Recombinant Fusion Proteins; D007987:Gonadotropin-Releasing Hormone